



Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17

November 12, 2015

-- Presentation to be webcast on www.exelixis.com --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 12, 2015-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at Stifel's 2015 Healthcare Conference, taking place November 17-18 in New York. The Exelixis presentation is scheduled for 3:00 PM EST/12:00 PM PST on Tuesday, November 17, 2015.

The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine kinases. Positive results were recently announced for a phase 3 pivotal trial of cabozantinib in patients with advanced renal cell carcinoma who received at least one prior VEGF receptor tyrosine kinase inhibitor, and Exelixis expects to complete regulatory filings in the U.S. and European Union in late 2015 and early 2016, respectively. Another Exelixis-discovered compound, COTELLIC™, a selective inhibitor of MEK, received its first regulatory approvals in Switzerland and the United States, and is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's website at www.exelixis.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151112006645/en/>

Source: Exelixis, Inc.

Exelixis, Inc.

Investors Contact:

Susan Hubbard, 650-837-8194

Investor Relations and Corporate Communications

shubbard@exelixis.com

or

Media Contact:

For Exelixis, Inc.

Hal Mackins, 415-994-0040

hal@torchcommunications.com